Robert Popovian, PharmD, MS

home / authors / robert-popovian-pharmd-ms

Robert Popovian is a leader in health care and biopharmaceuticals who is accomplished in pharmaceutical science, business and government, with a distinctive array of academic and practical experience across a wide range of healthcare and business management functions. Positioned at the intersection of economics, policy, and innovation which maximizes patient access.

Articles

woman wearing a face mask holding a vial of medicine

Contributor: What Is the Value of the Interchangeability Designation for a Biosimilar?

November 14th 2022

If every adalimumab biosimilar had an interchangeability designation, the United States could save additional $765 million annually, according to calculations from 3 biosimilar experts.

the US capitol building at sunset

Opinion: Biosimilar Adoption Will Help Achieve a Bipartisan Goal

April 25th 2022

Biosimilars provide significant savings and encourages competition in the biopharmaceutical marketplace but the United States needs to do more to empower uptake and address adoption barriers, according to Robert Popovian PharmD, MS.

© 2024 MJH Life Sciences

All rights reserved.